SCHLOSSER HUBERT (DE)
MUELLER INGRID (DE)
NONAKA TOSHIAKI (JP)
NAGAO KAZUYA (JP)
TAKEICHI AYAKO (JP)
FUJIWARA HIDENORI (JP)
WINGEN RAINER (DE)
ILLIAN GERHARD (JP)
SCHLOSSER HUBERT (DE)
MUELLER INGRID (DE)
NONAKA TOSHIAKI (JP)
NAGAO KAZUYA (JP)
TAKEICHI AYAKO (JP)
FUJIWARA HIDENORI (JP)
WINGEN RAINER (DE)
| EP0606090A1 | 1994-07-13 | |||
| EP0541081A2 | 1993-05-12 | |||
| EP0552658A1 | 1993-07-28 | |||
| EP0573878A1 | 1993-12-15 |
| 1. | A compound of the formula (I) R1 iA ) M ) (A2)h(M2) (A3)r(M ( I ) in which the symbols and indices have the following meanings: R1 is a straightchain or branched alkyl radical having 1 to 22 carbon atoms (with or without an asymmetrical carbon atom) in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, S, CO, CO0, 0CO, COS, SCO, 0CO0, CHCH, C≡C, . Δ, or Si(CH3)2, and in which, in addition, one or more hydrogen atoms of the alkyl radical may be substituted by F, Cl, Br or CN, or is one of the chiral groups below: *«mιm SHEET „ R2 CCO0. R2.CC0O, I C 1 CH2CH20, CH, CH, I I R20*CCO0. R20CO«C0 H H 0C0 SUBSTITUTE SHEET (RULE 26) wherein, R2, R3, R4 and R5, independently of one another, are H or a straightchain or branched alkyl radical having 1 to 22 carbon atoms in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, S, CO, CO0, 0CO, COS, SCO, 0CO0, CH=CH, C≡C, A., or Si(CH3)2, or R2 and R3 together may alternatively be (CH2)4 or (CH2)5 if they are bonded as substituents to a dioxolane system; and M4 is CH20, 0CH2, CO0, OCO or a single bond; A1, A2 and A3 are identical or different and are 1,4phenylene, in which one or two hydrogen atoms may be replaced by F, Cl and/or CN, pyrazine2,5diyl, pyridazine3,6diyl, pyridine2,5diyl or pyrimidine2,5diyl, in which one or two hydrogen atoms may be replaced by F, transl,4cyclohexylene, in which one or two hydrogen atoms may be replaced by CN and/or CH3, 1,3,4thiadiazole2,5diyl, 1,3dioxane2,5diyl, 1,3dithiane2,5diyl, 1,3thiazole2,4diyl, 1,3thiazole2,5diyl, thiophene2,4diyl, thiophene2,5diyl, piperazine1,4diyl, piperazine2,5diyl or naphthalene2,6diyl; M1 and M2 are identical or different and are a single bond, 0, S, CO, CO0, 0C0, C0S, SCO, 0CO0, CH20, 0CH2, CH2CH2, CH=CH or C≡C; M3 is a single bond or a straightchain or branched alkyl radical having 1 to 16 carbon atoms in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, S, CO, CO0, 0CO, COS, SCO, 0CO0, CH=CH, C≡C or Si(CH3)2, and in which, in addition, one or more hydrogen atoms of the alkyl radical may be substituted by F, Cl, Br or CN, with the proviso that M3 is not 0COCH2CH2; a, b and c are zero or one, with the proviso that the sum a+b+c is. |
| 2. | or 3; and * is a chiral center; provided however that when A1 and A2 are 1,4phenylene, M1 and M2 are a single bond, c is zero and M3 is CO0, then R1 is not C8H170. |
| 3. | 2 A compound as claimed in Claim 1, in which the symbols and indices in the formula (I) have the following meanings: R1 is a straightchain or branched alkyl radical having 1 to 22 carbon atoms (with or without an asymmetrical carbon atom) in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, S, CO, CO0, 0CO, 0CO0, CH=CH, C≡C, A., or Si(CH3)2, or is one of the chiral groups below: H H R2,CCH2CO0 , R2<CCH2CH20> C 1 A 1 SUBSTITUTE SHEET (RU 26) R20. wherein, R2, R3, R4 and R5, independently of one another, are H or a straightchain or branched alkyl radical having 1 to 22 carbon atoms in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, S, CO, CO0, 0CO, C0S, SCO, 0CO0, CH=CH, C≡C, _A., or Si(CH3)2, or R2 and R3 together may alternatively be (CH2)4 or (CH2)5 if they are bonded as substituents to a dioxolane system; A1, A2 and A3 are identical or different and are 1,4phenylene, pyrazine2,5diyl, pyridazine3,6diyl, pyridine2,5diyl or pyrimidine2,5diyl, in which one or two hydrogen atoms may be replaced by F, transl,4cyclohexylene, 1,3,4thiadiazole2,5diyl, l,3dioxane2,5diyl or naphthalene2,6diyl; M1 and M2 are identical or different and are a single bond, 0, CO, CO0, 0CO, CH20, 0CH2, CH2CH2, CH=CH or C≡C; M3 is a single bond or a straightchain or branched alkyl radical having 1 to 16 carbon atoms in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, CO, C00, OCO or 0C00, and in which, in addition, one or more hydrogen atoms of the alkyl radical may be substituted by F, Cl, Br or CN; and a, b and c are zero or one, with the proviso that the sum a+b+c is 2 or 3. |
| 4. | 3 A compound as claimed in Claim 1, in which the symbols and indices in the formula (I) have the following meanings: R1 is a straightchain or branched alkyl radical having 1 to 22 carbon atoms (with or without an asymmetrical carbon atom) in which, in addition, it is possible for one or two nonadjacent CH2 groups to be replaced by 0, CO, CO0, 0C0, CH=CH, C≡C, __Δ_, or Si(CH3)2; A1, A2 and A3 are identical or different and are 1,4phenylene, in which one or two hydrogen atoms may be replaced by F, pyrazine2,5diyl, pyridine2,5diyl, pyrimidine2,5diyl, trans1,4cyclohexylene, 1,3,4thiadiazole2,5diyl, naphthalene2,6diyl or 1,3dioxane2,5diyl; M1 and M2 are identical or different and are a single bond, 0, CO0, 0CO, CH20, 0CH2, CH2CH2, CH=CH or C≡C; M3 is a single bond, CO0, 0CO 0COCnH2n or 0CnH2n (wherein n is an integer from 1 to 10); and a, b and c are zero or one, with the proviso that the sum a+b+c is 2 or 3. |
| 5. | A compound as claimed in Claim 1 selected from the group consisting of the following compounds: in which either of X and Y is a straightchain or branched alkyl radical having 1 to 22 carbon atoms, wherein one CH2 group may be replaced by 0, _Δ_, CH=CH, COO or Si(CH3)2; and the other is wherein M3 is a single bond, CO0 , 0CO , 0COCnH2n or 0CnH2n ( wherein n is an integer from 1 to 10 ) . SUBSTITUTE SHEET (RULέ 26) . |
| 6. | A compound as claimed in Claim 1 selected from the group consisting of the following compounds: ■©©©■ in which either of X and Y is a straightchain or branched alkyl radical having 1 to 22 carbon atoms, wherein one CH2 group may be replaced by 0 or C00; and the other is wherein M3 is 0CO or 0CH2, . |
| 7. | A compound as claimed in Claim 1, in which the symbols and indices in the formula (I) have the following meanings: R1 is a straightchain or branched alkyl radical having 1 to 22 carbon atoms, in which one CH2 group may be replaced by O or CO0; and the group (A^^M1)(A2)b(M2)(A3)c( 3) is any one of the following groups: . |
| 8. | A smectic liquidcrystal composition or a ferroelectric liquidcrystal composition containing at least one compound as claimed in Claim 1. |
The present invention relates to a novel compound for use in liquid-crystal compositions.
In particular in the last decade, liquid crystals have been introduced into various technical areas where electro-optical and display device properties are required (for example, in watch, calculator and typewriter displays). These display devices are based on the dielectric alignment effects in the nematic, cholesteric and/or smectic phases of the liquid-crystalline compounds, where, caused by the dielectric anisotropy, the molecular long axes of the compounds adopt a preferred alignment in an applied electric field. The conventional response times in these display devices are too long for many other potential areas of application of liquid crystals. This disadvantage is particularly noticeable if a large number of pixels have to be addressed. The production costs of equipment containing relatively large screen areas are then generally too high.
In addition to nematic and cholesteric liquid crystals, optically active smectic liquid-crystal phases have also been increasing in importance for a few years.
Clark and Lagerwall have been able to show that the use of ferroelectric liquid-crystal systems in very thin cells give electro-optical switch or display elements which have response times faster by a factor of up to 1000 compared with conventional TN ("twisted nematic") cells (cf., for example, Lagerwall et al., "Ferroelectric Liquid Crystals for Displays", SID Symposium, October Meeting 1985, San Diego, Ca. , USA). Due to these and other favorable properties, for example, the possibility for bistable switching and the contrast which is virtually independent of the viewing angle, FLCs are fundamentally very suitable for the above-mentioned
areas of application, for example, via matrix addressing. Due to their high contrast and speed, ferroelectric liquid crystals are also particularly suitable in the area of spatial light modulators (cf, for example, U. Efron in "Spatial Light Modulators and Applications", SPIE, Vol. 1150, p. 46 ff).
Ferroelectric properties are expressed in liquid crystals having a phase called a smectic phase represented by a smectic C phase. Compounds having a smectic phase are described in, for example, G. W. Gray et al., Mol. Cryst. Liq. Cryst., Vol. 37, 157-188 (1976). The working temperature and the storage temperature of such liquid-crystal display devices are restricted by the temperatures range of a smectic C phase. Hence ferroelectric liquid crystals having a smectic C phase in a temperature range of -20 °C to +70 °C are desired.
The above requirements can only be satisfied by mixing a plurality of components. In addition, a material which can reduce the melting point and raise the upper limit of the phase transition temperature of a smectic C phase is always required. Compounds bearing a very short alkyl or alkyloxy radical on only one side of the molecule tend to have a nematic phase. It has been an established technique in the art to use such compounds as a component of nematic liquid crystal compositions (Japanese Patent Public Disclosure No. 148282/1986 and No. 003451/1980). However, they have not been considered to be useful for ferroelectric liquid-crystal compositions.
Accordingly, the object of the present invention is to provide a compound capable of broadening the temperature range of a smectic C phase and to provide a liquid-crystal composition containing the compounds.
Surprisingly, it has now been found that compounds which include as a terminal group a cyclohexyl group having no side chains have a smectic C phase and are useful for broadening
the temperature range of the smectic C phase and reducing the melting point of smectic liquid-crystal compositions and ferroelectric liquid crystals.
The present invention relates to compounds of the formula (I):
R 1 - ( A 1 ) J - M 1 ) (-A 2 ) h (-M 2 ) (-A 3 ) ( 3 ) ( I )
in which the symbols and indices have the following meanings:
R 1 is a straight-chain or branched alkyl radical having 1 to 22 carbon atoms (with or without an asymmetrical carbon atom) in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -S-, -CO-, -CO-0-, -0-CO-, -C0-S-, -S-CO-, -0-CO-0-, -CH=CH-, -C≡C-, Λ , or -Si(CH 3 ) 2 -, and in which, in addition, one or more hydrogen atoms of the alkyl radical may be substituted by F, Cl, Br or CN, or is one of the chiral groups below:
H H R 2 - C-CO-0-. R 2 - 4 C-C0-0-.
I
C 1 F
H
R 2 -„C-CH 2 -0- . R 2 -,C-CH,-0- .
C 1
H 2 -0
CH. CH.
R 2 -0-,C-CO-0-, R 2 -0-CO-,C-0-
H H
-CO- ,
wherein,
R 2 , R 3 , R 4 and R 5 , independently of one another, are H or a straight-chain or branched alkyl radical having 1 to 22 carbon atoms in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -S-, -CO-, -CO-0-, -0-CO-, -CO-S-, -S-C0-, -0-CO-0-, -CH=CH-, -C≡C-,___A, or -Si(CH 3 ) 2 -, or R 2 and R 3 together may alternatively be -(CH 2 ) 4 - or -(CH 2 ) 5 - if they are bonded as substituents to a dioxolane system; and
M 4 is -CH 2 -0-, -0-CH 2 -, -CO-0-, -O-CO- or a single bond;
A 1 , A 2 and A 3 are identical or different and are 1,4-phenylene, in which one or two hydrogen atoms may be replaced by F, Cl and/or CN, pyrazine-2,5-diyl, pyridazine-3,6-diyl, pyridine-2,5-diyl or pyrimidine-2,5-diyl, in which one or two hydrogen atoms may be replaced by F, trans-l,4-cyclohexylene, in which one or two hydrogen atoms may be replaced by -CN and/or -CH 3 , 1,3,4-thiadiazole-2,5-diyl, 1,3-dioxane-2,5-diyl, 1,3-dithiane-2,5-diyl, 1,3-thiazole-2 f ,4-diyl, l,3-thiazole-2,5-diyl, thiophene-2,4-diyl, thiophene-2,5-diyl, piperazine-1,4-diyl, piperazine-2,5-diyl or naphthalene-2,6-diyl;
M 1 and M 2 are identical or different and are a single bond, -0-, -S-, -CO-, -CO-0-, -0-CO-, -CO-S-, -S-CO-, -0-CO-0-, -CH 2 -0-, -0-CH 2 -, -CH 2 CH 2 -, -CH=CH- or -C≡C-;
M 3 is a single bond or a straight-chain or branched alkyl radical having 1 to 16 carbon atoms in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -S-, -CO-, -CO-0-, -0-CO-, -CO-S-, -S-CO-, -0-CO-0-, -CH=CH-, -C≡C- or -Si(CH 3 ) 2 -, and in which, in addition, one or more hydrogen atoms of the alkyl radical may be substituted by F, Cl, Br or CN, with the proviso that M 3 is not -0-CO-CH 2 CH 2 -; a, b and c are zero or one, with the proviso that the
sum a+b+c is 2 or 3; and
* is a chiral center; provided however that when A 1 and A 2 are 1,4-phenylene, M 1 and M 2 are a single bond, c is zero and M 3 is -CO-0-, then R 1 is not C 8 H 17 -0-.
The present invention further relates to liquid-crystal compositions containing at least one compound of the formula (I) or a mixture thereof.
Preference is given to the compounds of the formula (I) in which the symbols and indices have the following meanings:
R 1 is a straight-chain or branched alkyl radical having 1 to 22 carbon atoms (with or without an asymmetrical carbon atom) in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -S-, -CO-, -C0-0-, -0-C0-, -0-C0-0-, -CH=CH-, -C≡C-,_Δ_, or -Si(CH 3 ) 2 -, or is one of the chiral groups below:
CH 2 CH 2 -0-.
R 2 -O -
R 2 -,
wherein,
R 2 , R 3 , R 4 and R 5 , independently of one another, are H or a straight-chain or branched alkyl radical having 1 to 22 carbon atoms in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -S-, -CO-, -CO-0-, -0-CO-, -CO-S-, -S-CO-, -0-CO-0-, -CH=CH-, -C≡C-, .A, or -Si(CH 3 ) 2 -, or R 2 and R 3 together may alternatively be -(CH 2 ) 4 - or -(CH 2 ) 5 - if they are bonded as substituents to a dioxolane system; A 1 , A 2 and A 3 are identical or different and are 1,4-phenylene, in which one or two hydrogen atoms may be replaced by F, pyrazine-2, 5-diyl, pyridazine-3, 6-diyl, pyridine-2, 5-diyl, pyrimidine-2,5-diyl, trans-1,4-cyclohexylene, 1,3,4-thiadiazole-2, 5-diyl, l,3-dioxane-2, 5-diyl or naphthalene-2,6-diyl;
M 1 and M 2 are identical or different and are a single bond, -0-, -CO-, -CO-0-, -0-CO-, -CH 2 -0-, -0-CH 2 -, -CH 2 CH 2 -, -CH=CH- or -C≡C-;
M 3 is a single bond or a straight-chain or branched alkyl radical having 1 to 16 carbon atoms in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -CO-, -CO-0-, -O-CO- or -0-CO-0-, and in which, in addition, one or more hydrogen atoms of the alkyl radical may be substituted by F, Cl, Br or CN; and
a, b and c are zero or one, with the proviso that the sum a+b+c is 2 or 3.
Particular preference is given to the compounds of the formula (I) in which symbols and indices have the following meanings:
R 1 is a straight-chain or branched alkyl radical having 1 to 22 carbon atoms (with or without an asymmetrical carbon atom) in which, in addition, it is possible for one or two non-adjacent -CH 2 - groups to be replaced by -0-, -CO-, -C0-0-, -0-C0-, -CH=CH-, -C≡C-,_Λ, or -Si(CH 3 ) 2 -;
A 1 , A 2 and A 3 are identical or different and are 1,4-phenylene, in which one or two hydrogen atoms may be replaced by F, pyrazine-2,5-diyl, pyridine-2,5-diyl, pyrimidine-2,5-diyl, trans-1,4-cyclohexylene, 1,3,4-thiadiazole-2,5-diyl, naphthalene-2,6-diyl or 1,3-dioxane-2,5-diyl;
M 1 and M 2 are identical or different and are a single bond, -0-, -C0-0-, -0-C0-, -CH 2 -0-, -0-CH 2 -, -CH 2 CH 2 -, -CH=CH- or -C≡C-;
M 3 is a single bond, -C0-0-, -0-C0-, -0-C0-C n H 2n - or -0-C n H 2n - (wherein n is an integer from 1 to 10); and a, b and c are zero or one, with the proviso that the sum a+b+c is 2 or 3.
Of the compounds of the formula (I) according to the present invention, the followings are particularly preferable:
in which either of X and Y is a straight-chain or branched alkyl radical having 1 to 22 carbon atoms, wherein one -CH 2 - group may be replaced by -0-,__-Δ., -CH=CH-, -CO-O- or -Si(CH 3 ) 2 -; and the other is
wherein M 3 is a single bond, -CO-0-, -0-CO-, -O-CO-C H, - or -0-C n H 2n - (wherein n is an integer from 1 to 10).
Very particular preference is given to the following
SUBSTITUTESHEfT(RULE26 )
compounds :
in which either of X and Y is a straight-chain or branched alkyl radical having 1 to 22 carbon atoms, wherein one -CH 2 - group may be replaced by -0- or -C0-0-; and the other is
wherein M 3 is -0-CO- or -0-CH 2 -, and the compounds of the formula (I) wherein:
R 1 is a straight-chain or branched alkyl radical having 1 to 22 carbon atoms, in which one -CH 2 - group may be replaced by -O- or -C0-0-; and the group -(A x ) a (-M 1 )(-A 2 ) b (-M 2 )(-A 3 ) c (-M 3 )- is any one of the following groups:
The compound of the formula (I) according to the present invention is suitable as a component for liquid-crystal compositions, in particular ferroelectric liquid-crystal compositions. The liquid-crystal compositions may contain from 0.01 to 60 % by weight, preferably from 0.1 to 40 % by weight, particularly preferably from 0.1 to 20 % by weight, of the compounds according to the present invention. The other constituents are preferably selected from known compounds having nematic, cholesteric and/or smectic phases; these include, for example, Schiff's bases, biphenyls, terphenyls, phenylcyclohexanes, cyclohexylbiphenyls, N-, S- or O-containing heterocyclic compounds, for example pyrimidines, cinnamic acid esters, cholesterol esters or various bridged, polycyclic esters of p-alkylbenzoic acids which have terminal polar groups.
Surprisingly, it has now been found that the addition of compounds of the formula (I) can considerably broaden the temperature range in a lower temperature region of smectic C compositions or the smectic C phase of ferroelectric liquid-crystal compositions.
These mixtures can in turn be used in electro-optical or fully optical elements, for example, display elements, switching elements, light modulators, elements for image processing, signal processing or generally in the area of non-linear optics.
The present invention is described in greater detail by means of Examples below.
The phase transition temperatures were determined with the aid of a polarizing microscope from the changes in texture on heating. By contrast, the melting point was determined using a DSC instrument. The phase transition temperatures between the phases isotropic (I) nematic (N or N*) smectic-C (S c or S c *)
smectic-A (S A ) crystalline (X) are given in °C, and the values are between the phase designations in the phase sequence. Example 1 4-(5-Octyloxypyrimidine-2-yl)phenyl cyclohexylcarboxylate
1.00 g of 4-(5-octyloxypyrimidine-2-yl) was dissolved in 12 ml of pyridine, and the solution was cooled on an ice bath. 4 g of cyclohexyl carbonylchloride was slowly added dropwise to the solution. The solution was left at room temperature overnight and poured into ice water. After the solution was adjusted to pH 2 with concentrated hydrochloric acid, an ester was precipitated. The solution was filtered and recrystallized from n-hexane to give 600 mg of 4-(5-octyloxypyrimidine-2-yl)phenyl cyclohexylcarboxylate.
The compound has the following phase sequence: X 107 I Example 2
4-[2-(4'-Octyloxyphenyl)pyrimidine-5-yl]phenyl cyclohexylcarboxylate
The synthesis was carried out analogously to Example 1 , The compound has the following phase sequence: X 154.9 I
Example 3
4- ( 5-Octylpyrimidine-2-yl )phenyl cyclohexylcarboxylate
-
The synthesis was carried out analogously to Example 1 The compound has the following phase sequence: X 96.7 I
Example 4
2-(4-0ctyloxyphenyl)pyrimidine-5-yl
4-cyclohexylphenylcarboxylate
The synthesis was carried out analogously to Example 1.
The compound has the following phase sequence: X 108 (73) N 206 I Example 5 4-( 5-0ctyl-l,3-dioxane-2-yl)phenyl cyclohexanecarboxylate
The synthesis was carried out analogously to Example 1. The compound has the following phase sequence: X 82 (22.5) S 2 61 S x 75 I
Example 6
4-(5-Octyl-l,3-dioxane-2-yl)phenyl
4-cyclohexylphenylcarboxylate
The synthesis was carried out analogously to Example 1, The compound has the following phase sequence: X 2 99 X 106 (78) N 169 I
Example 7
2-(4-Cyclohexylphenyl)pyrimidine-5-yl undecanoate
The synthesis was car out analogously to Example 1, The compound has the following phase sequence: X 99.9 (88) I
Example 8
2-(4-Cyclohexylphenyl)pyrimidine-5-yl heptanoate
The synthesis was carried out analogously to Example 1 , The compound has the following phase sequence: X 109.3 ( 100 ) I
Example 9
4-(5-Octyloxypyrimidine-2-yl)phenyl
4-cyclohexylphenylcarboxylate
The synthesis was carried out analogously to Example 1.
The compound has the following phase sequence: X 144 (122) N 200 I Example 10 4-(5-Octylpyridine-2-yl)phenyl 4-cyclohexylphenylcarboxylate
The synthesis was carried out analogously to Example 1.
The compound has the following phase sequence: X 133 (117) N 182 I Example 11 4'-Octyloxylphenyl 4-cyclohexylbenzoate
The synthesis was carried out analogously to Example 1. The compound has the following phase sequence: X 92 (78) I
Example 12
Hydroquinone 4-octyloxyphenylcarboxylate
4-cyclohexylphenylcarboxylate diester
The synthesis was carried out analogously to Example 1, The compound has the following phase sequence: X 146 (114) N 212 I
Example 13
2-(4-Cyclohexylphenyl)-5-(4-nonyloxyphenyl)-1,3,4- thiadiazole
The synthesis was carried out analogously to the method described by K. Dimitrooa, F. Hauschild, H. Azschke and H. Schubert in Journal fur Prakt. Chemie, Vol. 322 (1980), page 933.
The compound has the following phase sequence: X 126 S c 146 N 186 I Example 14 2-Cyclohexyl-5-(4-nonyloxyphenyl)-1,3,4-thiadiazole
The synthesis was carried out analogously to Example 13, The compound has the following phase sequence: X 2 77 X 86 S A 67 I
Example 15
2-[4'-(4-Cyclohexyl-n-butyloxy)phenyl]-5-octylpyrimidine
The synthesis was carried out according to the method described in European Patent No. 0318423 and No. 0398155.
The compound has the following phase sequence: X 42 (11) S c 41 S A 43 N 51 I Example 16 2-[4-(6-Cyclohexyl-n-hexyloxy)phenyl]-5-octylpyrimidine
The synthesis was carried out analogously to Example 15.
The compound has the following phase sequence: X 56 (10) S c 51 S s 52 N 57 I Example 17 2-[4'-(9-Cyclohexyl-n-nonyloxy)phenyl]-5-octylpyrimidine
The synthesis was carried out analogously to Example 15. The compound has the following phase sequence: X 73 (67) N 60 I
Example 18
2-[4'-(9-Cyclohexyl-n-nonyloxy)phenyl]-5-dodecylpyrimidin e
The synthesis was carried out analogously to Example 15.
The compound has the following phase sequence: X 78 (65) S c 75 I Example 19 2-[4-(4-Cyclohexylbutylox )phenyl]-5-octyloxypyrimidine
The synthesis was carried out analogously to Example 15.
The compound has the following phase sequence: X 71 (51) S c 79 S A 81 N 84 I Example 20 2-[4-(4-Cyclohexylhexyloxy)phenyl]-5-octyloxypyrimidine
The synthesis was carried out analogously to Example 15, The compound has the following phase sequence: X 55 (41) S c 81 S A 87 N 88 I
Example 21
2-[4-( -Cyclohexyl-n-nonyloxy)phenyl]-5-octyloxypyrimidine
The synthesis was carried out analogously to Example 15.
The compound has the following phase sequence: X 73 (61) S c 86 S A 91 I Example 22 4-(5-Octylpyrimidine-2-yl)phenyl 7-cyclohexylheptoate
The synthesis was carried out analogously to Example 15, The compound has the following phase sequence:
X 2 69 X 71 I
Example 23
4-( 5-Decylpyrimidine-2-yl)phenyl 7-cyclohexylheptoate
The synthesis was carried out analogously to Example 15. The compound has the following phase sequence: X 2 62 (56) X 74 S c 64 I
Example 24
4-(5-Octyloxypyrimidine-2-yl)phenyl 7-cyclohexylheptoate
The synthesis was carried out analogously to Example 15, The compound has the following phase sequence: X 66 (58) S c 87 S A 88 N 90 I
Example 25
6-(4-Cyclohexylphenyl-2-fluoro-3-octyloxypyridine)
2.2 g (8.3 mmol) of triphenylphosphine and 1.3 ml (8.3 mmol) of diethyl azodicarboxylate were stirred in tetrahydrofuran at 0 °C for half an hour. 1.3 ml (8.3 mmol) of 1-octanol and 1.5 g (5.53 mmol) of 6-(4-cyclohexylphenyl)- 2-fluoro-3-hydroxypyridine were added therein and the mixture was stirred at room temperature for 18 hours.
The solution was evaporated to dryness, and the residue was purified by column chromatography. Recrystallization from acetonitrile gave 1.03 g of the titled compound.
The compound has the following phase sequence: X 86 (65) I Example 26 2-(4-Cyclohexylphenyl)-octyloxypyridine
The synthesis was carried out analogously to Example 25, The compound has the following phase sequence: X 68 (47) S 2 75 S c 84 N 89 I
Example 27
5-[4-(Cyclohexylmethyloxy)phenyl]-2-(4'-octyloxyphenyl)- pyrimidine
2 -
The synthesis was carried out analogously to Example 25, The compound has the following phase sequence: X 126 S 3 140 S c 183 S A 213 N 214 I
Example 28
2-[4-(Cyclohexylmethyloxy)phenyl)-5-octyloxypyrimidine
The synthesis was carried out analogously to Example 25, The compound has the following phase sequence: X 106 I
Example 29
2- ( 4-Cyclohexylphenyl ) -5-dodecyloxypyrimidine
The synthesis was carried out analogously to Example 25, The compound has the following phase sequence: X x 67 (32) X 2 71 (39) S c 75 S A 92 I
Example 30
2-(4-Cyclohexylphenyl)-5-decyloxypyrimidine
The synthesis was carried out analogously to Example 25, The compound has the following phase sequence: X 65 (23) S 3 74 S c 76 S A 89 N 89.2 I
Example 31
2-(4-Cyclohexylphenyl)-5-octyloxypyrimidine
The synthesis was carried out analogously to Example 25.
The compound has the following phase sequence: X l 55 X 2 71 (62) S 2 67 S A 78 N 85 I Example 32 5-(4-Cyclohexylphenyl)-2-octyloxypyrimidine
-^-°~(O)-(Q)- )
2 g (6.96 mmol) of 5-bromo-2-octylpyrimidine, 1.42 g (6.96 mmol) of 4-cyclohexylbenzeneboronic acid, 1.5 g (14.00 mmol) of sodium carbonate and 0.08 g (0.07 mmol) of tetrakisphenylphosphine paradium were refluxed for 4 hours in 40 ml of toluene, 10 ml of ethanol and 10 ml of water.
The organic phase was separated and evaporated to dryness, and the crude product was purified by column chromatography and recrystallized from acetanilide to give
SUBSTITUTESHEET(RULE 2β)
1.29 of the titled compound.
The compound has the following phase sequence: X 92.7 (65.4) S A 79 I Example 33 5-(4-Cyclohexylphenyl)-2-octyloxypyridine
The synthesis was carried out analogously to Example 32, The compound has the following phase sequence: X 64 (36.1) S B 60 I
Example 34
2-(4-Cyclohexylphenyl)-5-(4-hexylphenyl)pyrimidine
The synthesis was carried out analogously to Example 32.
The compound has the following phase sequence: X 129.8 (115) S 3 150 S c 153 S A 187 N 197 I Example 35
5-[4-(4-Butyldimethylsilyl)-butyloxyphenyl]-2-(4- cyclohexylphenyl)pyrimidine
The synthesis was carried out analogously to Example 32, The compound has the following phase sequence: X 145.7 (140) S j, 152 I
Example 36
5-(4-Cyclohexylphenyl)-2-(4-hexylphenyl)pyrimidine
The synthesis was carried out analogously to Example 32, The compound has the following phase sequence: X 147 (133) S A 209 I
Example 37
5-(4-Cyclohexylphenyl)-2-(4-octyloxyphenyl)pyrimidine
H π -0 zδ y oy
The synthesis was carried out analogously to Example 32.
The compound has the following phase sequence: X 134 (90) S 3 94 S c 134 S A 210 N 219 I Example 38
2-[4-(4-Butyldimethylsilyl)butyloxyphenyl]-5-(4-cyclohexy l- phenyl)pyrimidine
The synthesis was carried out analogously to Example 32. The compound has the following phase sequence: X 97 (70) S c 117 S A 199 I
Example 39
6- ( 4-Cyclohexylphenyl ) -2-fluoro-3- ( 4-octyloxyphenyl )pyridine
The synthesis was carried out analogously to Example 32, The compound has the following phase sequence: X 115 (78) S 0 99 S c 141 N 187 I
Example 40
3- ( 4-Cyclohexylphenyl )-2-fluoro-6-octyloxypyridine
The synthesis was carried out analogously to Example 32.
The compound has the following phase sequence: X 49 (11) I Example 41 2-(4-Cyclohexylphenyl)-5-(4-octyloxyphenyl)pyrimidine
The synthesis was carried out analogously to Example 32, The compound has the following phase sequence: X 102 (73) S B 144 S c 188 S A 214 N 217 I
Example 42
2-(4-Cyclohexylphenyl)-5-octylpyrimidine
2.9 ml (17 mmol) of 1-bromooctane and 0.51 g (21 mmol) of a Grignard compound were reacted in 50 ml of tetrahydrofuran. The Grignard compound solution was added dropwise to a solution of 3 g (9.5 mmol) of 5-bromo-2-(4-cyclohexylphenyl)- pyrimidine and 0.06 g (0.1 mmol) of 1,3-bis(diphenyl- phosphine)propane nickel (II) chloride in 65 ml of tetrahydrofuran, and the mixture was stirred at 0 °C for 2 to 4 hours.
3 ml of hydrochloric acid (37 % strength) and 50 ml of water were added therein, the organic phase was separated, washed, dried over Na 2 S0 4 , filtered and evaporated to dryness. The product was purified by column chromatography and recrystallized from acetanilide to give 0.83 g of the titled compound.
The compound has the following phase sequence: X x 18.5 (5) X 2 69 S B 76 (71) I Example 43 Trans-5-cyclohexyl-2-[4-(4-pentylcyclohexyl)phenyl]pyrimidin e
The synthesis was carried out analogously to Example 42, The compound has the following phase sequence: X 140 (113) N 214 I
Example 44
A ferroelectric liquid-crystal composition (A) containing the compounds (a) and (b) of the present invention comprises the following components (mol %).
αnS
' H π- o p Hjθ - 0 - co -°- C B H I 3
The composition (A) has the following phase sequence: X -26 S c * 70 S A 73 Ch* 87 I
The above example shows that the compound of the present invention gives a very low melting point and a broad temperature range of smectic C phase.
In addition, the composition (A) can be used for ferroelectric liquid-crystal display devices, and switches at a switching speed of 44 μs by means of a dipolar pulse.
Example 45
A ferroelectric liquid-crystal composition (B) containing no compounds of the present invention comprises the following components (mol %).
l H 1-to)- θy- O - C 10 H 21
l H 1- 0 - θ C °-°- θ 0 - C 6 H 13
l H 17-°
C 8 H π - 0 - C0 - 0 - θ)— θ 0_C B H 17
The composition (B) has the following phase sequence: X -19 S c * 76 S A 85 Ch* 101 I
A ferroelectric liquid-crystal composition (C) comprising 94 % of the composition (B) and 6 % of the compound (c) of the present invention was prepared.
The composition (C) has the following phase sequence: X -27 S c * 72 S A 85 Ch* 96 I
The melting point was lowered by adding the liquid-crystal compound (c) of the present invention to the ferroelectric liquid-crystal composition (B). Example 46
A ferroelectric liquid-crystal composition (D) containing the compounds of the present invention comprises the following components (mol %).
, H „-/ O V- O V° - C ° - C 9 H ID
C 8 H " — <δ δ>→»- C B 8H n 17
The composition (D) has the following phase sequence: X -22 S c 74 S A 83 Ch 88 I
Liquid-crystal compositions (E) and (F) were prepared by adding the compounds of the present invention to the composition (D). The smectic liquid-crystal composition (E) comprises 90 % of the composition (D) and 10 % of the compound (d) of the present invention.
The composition (E) has the following phase sequence:
X -31 S c 75 S A 84 Ch 97 I
On the other hand, the smectic liquid-crystal composition (F) comprises 90 % of the composition (D) and 10 % of the compound (e) of the present invention.
SUBSTITUTE SHEET (ft E 26)
The composition (F) has the following phase sequence: X -40 S c 80 S A 89 Ch 102 I
The melting point was lowered by adding the liquid-crystal compound (d) or (e) according to the present invention to the smectic liquid-crystal composition (D). Example 47
A smectic liquid-crystal composition (G) containing no compounds of the present invention comprises the following components (mol %).
12 CoH «-©-@-- C 10 H 21
13 1 H π- 0 - θ C °"°- θ - 0 " CceH"i3
SW UTE SHEET (RULE 26)
The composition (G) has the following phase sequence: X -7 S c 68 S A 71 Ch 85 I
Liquid-crystal compositions (H) and (I) were prepared by adding the compound (f) or (g) of the present invention to the composition (G). The smectic liquid-crystal composition (H) comprises 90 % of the composition (G) and 10 % of the compound (f) of the present invention.
The composition (H) has the following phase sequence:
X -13 S c 72 S A 77 Ch 86 I
On the other hand, the smectic liquid-crystal composition (I) comprises 80 % of the composition (G) and 20 % of the compound (g) of the present invention.
The composition (I) has the following phase sequence: X -14 S c 69 S A 76 C 87 I
The melting point was lowered by adding the liquid-crystal compound (f) or (g) of the present invention to the smectic liquid-crystal composition (G). Example 48
A liquid-crystal composition (J) containing no compounds of the present invention comprises the following components
(mol %).
12 CAH>- ^-- ^-0-C.H 1T
ιHj
12 C,H ls -0 - -©-"*-
10 C T E, -^HQH'-
The composition (J) has the following phase sequence: X 35 S c * 71 S A 88 Ch* 95 I
A liquid-crystal composition (K) containing 85 % of the composition (J) and 15 % of the compound (a) of the present invention was prepared.
The composition (K) has the following phase sequence: X -6 S c 73 S A 86 Ch 98 I
The melting point was lowered by adding the liquid-crystal compound (a) of the present invention to the liquid-crystal composition (J).
Ferroelectric liquid-crystal compositions (L) and (M) were prepared by adding the following compounds to 83 % of liquid-crystal compositions (J) and (K) respectively.
"t rtS
The ferroelectric liquid-crystal compositions (L) and (M) have the following phase sequence:
(L) X -7 S c * 73 S A 90 Ch* 91 I
(M) X -13 S c * 73 S A 87 Ch* 92 I
The ferroelectric liquid-crystal composition (M) has a low melting point.
The ferroelectric liquid-crystal composition has a spontaneous polarization of 53 nC/cm 2 , and it can be used for dielectric liquid-crystal display devices, and switches by means of a dipolar pulse. Example 49
A ferroelectric liquid-crystal composition (N) containing 8 % of the compound (a) of the present invention comprises the following components (mol %).
/°N
4H.-C C-CH HQHo ■ h-i αι-ιs
The ferroelectric liquid-crystal composition (N) has the following phase sequence:
X -8 S c * 64 S A 80 Ch* 84 I
The above low melting point was accomplished by the compound of the present invention.
In addition, the ferroelectric liquid-crystal composition (N) of the present invention has a spontaneous polarization of 40 nC/cm 2 , and it can be used for dielectric liquid-crystal display devices, and switches by means of a dipolar pulse.
The above Examples conform that the compounds according to the present invention can be used to prepare smectic or ferroelectric liquid-crystal compositions having a broad temperature range of a smectic C phase, particularly having a broad temperature range in a lower temperature region. Referential Example 4-(5-0ctyloxypyrimidine-2-yl)phenyl 3-cyclohexylpropionate
The synthesis was carried out analogously to Example 15. The compound has the following phase sequence: X 100 I